R. Diel a,*, T. Schaberg b, R. Loddenkemper c, T. Welte a, A. Nienhaus d


a Department of Pneumology, Medical School Hannover (MHH), Carl-Neuberg-Str.1, 30625 Hannover, Germany
b Center of Pneumology, Deaconess Hospital Rotenburg, Rotenburg/Wu¨mme, Germany
c German Central Committee against Tuberculosis, Berlin, Germany
d Institution for Statutory Accident Insurance and Prevention in the Health and Welfare Services, Hamburg, Germany
Received 10 June 2009; accepted 10 July 2009

Attachments:
Download this file (567_PUB_ART_Diel_Resp_Med_2009.pdf)567_PUB_ART_Diel_Resp_Med_2009.pdf[ ]369 kB

E. Laffitte, J.P. Janssens,* P. Roux-Lombard, A.M. Thielen, C. Barde, G. Marazza, R.G. Panizzon and J.-H. Saurat
Clinic of Dermatology, and Divisions of *Pulmonary Diseases and Immunology and Allergy, University Medical Hospital, CH-1211 Geneva, Switzerland
Clinic of Dermatology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland

Summary
Background Antitumour necrosis factor (anti-TNF) treatments may reactivate latent tuberculosis infection (LTBI). For detecting LTBI, the tuberculin skin test (TST) has low sensitivity and specificity. Interferon-c release assays (IGRA) have been shown to be more sensitive and specific than TST.

Attachments:
Download this file (549_PUB_ART_Laffitte_BJD_2009.pdf)549_PUB_ART_Laffitte_BJD_2009.pdf[ ]72 kB

YOSHIHIRO KOBASHI1, KEIJI MOURI1, NAOYUKI MIYASHITA1, NIRO OKIMOTO2, TOSHIHARU MATSUSHIMA3, TAKESHI KAGEOKA4 & MIKIO OKA1


From the 1Division of Respiratory Diseases, Department of Medicine, Kawasaki Medical School, Kurashiki, Japan, 2Division of Respiratory Diseases, Department of Medicine, Kawasaki Medical School, Kawasaki Hospital, Okayama, Japan, 3Department of Internal Medicine, Kurashiki Daiichi Hospital, Kurashiki, Japan, and 4Department of Laboratory Division, Kurashiki Central Hospital, Kurashiki, Japan

Attachments:
Download this file (568_PUB_ART_Kobashi_SJID_2009.pdf)568_PUB_ART_Kobashi_SJID_2009.pdf[ ]58 kB

Erwin Kaala,b,∗, Arend H.J. Kolka,c, Sjoukje Kuijpera,c, Hans-Gerd Janssena,d


a Polymer-Analysis Group, Van ’t Hoff Institute for Molecular Sciences, University of Amsterdam, Nieuwe Achtergracht 166, 1018 WV Amsterdam, The Netherlands
b ATAS GL International, P.O. Box 17, 5500 AA Veldhoven, The Netherlands
c KIT Biomedical Research, Royal Tropical Institute, Meibergdreef 39, 1105 AZ Amsterdam, The Netherlands
d Unilever Research and Development, Advanced Measurement and Imaging, P.O. Box 114, 3130 AC Vlaardingen, The Netherlands

Article history:
Received 6 April 2009
Received in revised form 24 June 2009
Accepted 30 June 2009
Available online 5 July 2009

Attachments:
Download this file (569_Kaal_J_Chrom_2009.pdf)569_Kaal_J_Chrom_2009.pdf[ ]575 kB

AKIRA FUJITA, KENGO MURATA AND MIKIO TAKAMORI
Department of Pulmonary Medicine, Tokyo Metropolitan Fuchu Hospital, Tokyo, Japan

ABSTRACT
Background and objective: The Lung Flute is a small self-powered audio device that generates sound waves, which vibrate in tracheobronchial secretions. This was a preliminary trial to evaluate the usefulness of the Lung Flute for sputum sampling in patients suspected of pulmonary tuberculosis (TB).

Attachments:
Download this file (548_PUB_ART_Fujita_Resp_2009.pdf)548_PUB_ART_Fujita_Resp_2009.pdf[ ]136 kB

J. L. Burgos,* J. G. Kahn,† S. A. Strathdee,* A. Valencia-Mendoza,‡ S. Bautista-Arredondo,‡ R. Laniado-Laborin,§ R. Castañeda,§ R. Deiss,* R. S. Garfein*


* Division of Global Public Health, School of Medicine, University of California San Diego, San Diego, California, † Philip R. Lee Institute for Health Policy Studies and Department of Epidemiology & Biostatistics, University of California San Francisco, San Francisco, California, USA; ‡ Dirección de Economía de la Salud, Instituto Nacional de Salud Pública, Cuernavaca, § Facultad de Medicina, Universidad Autónoma de Baja California, Tijuana, México.

Attachments:
Download this file (530_PUB_ART_Burgos_IJTLD_2009.pdf)530_PUB_ART_Burgos_IJTLD_2009.pdf[ ]122 kB

Sobre a REDE-TB

A Rede Brasileira de Pesquisa em Tuberculose (REDE-TB) é uma Organização Não Governamental (ONG) de direito privado sem fins lucrativos, preocupada em auxiliar no desenvolvimento não só de novos medicamentos, novas vacinas, novos testes diagnósticos e novas estratégias de controle de TB, mas também na validação dessas inovações tecnológicas, antes de sua comercialização no país e/ou de sua implementação nos Programa de Controle de TB no País.


bt2

Contato

E-mail: redetb.rp@gmail.com

Tel: +55 (21)3938 - 2426
Tel/ Fax: +55 (21)3938 - 2431.

Endereço: Avenida Carlos Chagas Filho, 791, Cidade Universitária - Ilha do Fundão, Rio de Janeiro, RJ - Brasil. CEP: 21941-904

Assine a newsletter da REDE-TB

Curta REDE-TB no Facebook